Top 20 Pediatric Autoimmune Diseases and the Evidence for Vitamin D in Prevention and Treatment

Type 1 diabetes is the only childhood autoimmune disease with consistent, multi-study evidence that vitamin D in infancy is linked to lower risk, and childhood-onset lupus is the only one with a positive double-blind pediatric RCT for treatment. For most of the other 18 conditions the evidence is limited to low blood 25(OH)D measured at or after diagnosis. That kind of finding cannot separate cause from effect.

TL;DR

Most common (Western population data): autoimmune thyroiditis, celiac disease, psoriasis, vitiligo, type 1 diabetes, alopecia areata, JIA and pediatric IBD lead the list. A 2026 Norwegian national registry study found that 2.6% of children develop at least one of six major autoimmune diseases by age 18, with celiac disease most common, followed by type 1 diabetes and autoimmune thyroiditis.
Prevention evidence:
- Type 1 diabetes: the strongest pediatric signal. A Finnish birth cohort and meta-analyses of observational studies found that infant vitamin D supplementation was associated with about 29% lower odds (pooled OR 0.71). However, Mendelian randomization and maternal-intake studies are null.
- Adults: the VITAL RCT showed 2,000 IU/day reduced incident autoimmune disease overall (HR 0.78).[1]
Treatment evidence:
- Positive: childhood-onset SLE (50,000 IU/week RCT improved SLEDAI and fatigue). Thyroid antibody titres fall in adult Hashimoto's RCT meta-analyses.
- Small or inconsistent: new-onset type 1 diabetes (slower loss of insulin production in small trials).
- Null: JIA and pediatric Crohn's (RCTs found no effect on disease activity).[2][3]
- Topical only: psoriasis (calcipotriol creams work; oral vitamin D does not reliably help).[4]

Key Findings

How the list was ranked. No single study ranks all 20 conditions.
- The anchor is the 2026 Norwegian nationwide cohort (Lancet Child & Adolescent Health; 793,772 children; incidence 162.8 per 100,000 person-years across six diseases).[5]
- It is supplemented by a Finnish cohort reporting incidences per 100,000 children/year of 106.1 for type 1 diabetes, 55.0 for JIA, 46.0 for autoimmune thyroiditis and 23.7 for IBD (UC 16.3, CD 7.5).[6]
- Disease-specific population studies come from the US, Germany, the UK, Scotland, Canada and Sweden.
- Chronic conditions are ranked by prevalence. Acute or self-limiting ones (IgA vasculitis, Kawasaki disease, ITP) are placed by annual incidence. Ranks 10–20 are approximate and differ by country (e.g., Kawasaki disease is far more common in Japan and Korea than in Europe).
Classification ambiguities.
- Kawasaki disease and IgA vasculitis are immune-mediated vasculitides rather than classic autoantibody diseases.
- Psoriasis is autoimmune/autoinflammatory.
- Eosinophilic esophagitis (an allergen-driven Th2 disease) and PANS/PANDAS (contested diagnostic criteria) were deliberately excluded from the top 20.
Vitamin D evidence is weakest exactly where the confounding is strongest. Low 25(OH)D at diagnosis is reported in nearly every condition (IgA vasculitis 15.47 vs 22.48 ng/mL in controls; HSP 16 vs 29 ng/mL; Kawasaki disease lower in a 22-study meta-analysis).[7][8][9] But inflammation, malabsorption (celiac, IBD), steroid use and indoor confinement all lower 25(OH)D.[10]
Mendelian randomization (MR) studies are the main check against confounding. They test the effect of genetically lower vitamin D, which confounding cannot explain.[11]
- Null for: JIA (OR 1.00, 95% CI 0.76–1.33)[12] and type 1 diabetes (pooled ORs 0.97–1.02).[13][14]
- Supportive for: multiple sclerosis and psoriasis.[15]
- Null for vitiligo.[15]

Main Table

Rank	Disease	Approx. pediatric prevalence/incidence	Vitamin D prevention evidence	Vitamin D treatment evidence	Key references
------	---------	---------	---------	---------	------
1	Autoimmune (Hashimoto's) thyroiditis	Antibody-positive in 1–2% of school-age children and 6–8% of adolescents; incidence 46.0/100,000/yr (Finland)	Observational only: low 25(OH)D in AITD (OR for deficiency 3.21, 25 studies); AITD a VITAL component (non-significant alone)	Adult RCT meta-analyses positive for antibodies: TPOAb falls, greatest benefit if baseline 25(OH)D <20 ng/mL; no consistent TSH/FT4 effect; no pediatric RCTs	AITD meta-analysis Jiang 2022 RCT MA VitaminDWiki thyroid
------	---------	---------	---------	---------	-----
2	Celiac disease	~0.3–1% of children; most common childhood autoimmune disease in Norway	Mixed: TEDDY found U-shaped risk (infant 25(OH)D <30 or >75 nmol/L linked to autoimmunity); Norwegian maternal/cord 25(OH)D null	No RCTs on disease course; deficiency correction for bone only	TEDDY 2021 MoBa maternal/neonatal Norway 2026
------	---------	---------	---------	---------	-----
3	Psoriasis (incl. juvenile PsA)	0.71% of under-18s (Germany); rises from 0.12% at age 1 to 1.2% at 18	MR supports causal role of low 25(OH)D; psoriasis a VITAL component	Topical vitamin D analogues (calcipotriol) are standard therapy; oral D adult RCT meta-analyses null/marginal (PASI MD −0.45 at 6 mo, 4 RCTs); uncontrolled 35,000 IU/day pilot (n=9)	Augustin 2010 MR skin 2022 Formisano 2023 MA VitaminDWiki psoriasis/vitiligo
------	---------	---------	---------	---------	-----
4	Vitiligo	0.84% (ages 4–11) and 1.19% (12–17), clinician-adjudicated, US; global child estimate 0.24%	MR: no causal effect	Pediatric non-randomized study: 1,500–3,000 IU/day plus tacrolimus improved repigmentation (n=30); adult RCT of 5,000 IU/day plus NB-UVB (results unverified)	Hamzavi 2023 MR skin 2022 NCT04872257
------	---------	---------	---------	---------	-----
5	Type 1 diabetes	~1 in 500 children; incidence 106.1/100,000/yr (Finland)	Strongest pediatric signal: Finnish 1966 birth cohort (n=10,366); infant supplementation pooled OR 0.71 (0.60–0.84); maternal intake null (OR 0.95); MR null	Mixed small RCTs: ergocalciferol 50,000 IU weekly/biweekly and high-dose D3 slowed C-peptide decline; calcitriol trials null	Hyppönen 2001 Zipitis 2008 MA MR T1D Nallapu 2025 VitaminDWiki diabetes
------	---------	---------	---------	---------	-----
6	Alopecia areata	Prevalence 0.11%; incidence 13.6/100,000 person-yrs (US PEDSnet)	Observational only: ~4-fold higher odds of low 25(OH)D	RCT meta-analysis supports intralesional D3 (OR 3.20) and topical analogues; oral D in children (400–1,600 IU) gave no regrowth (n=12)	McKenzie 2022 Alsaati 2025 MA VitaminDWiki alopecia
------	---------	---------	---------	---------	-----
7	Juvenile idiopathic arthritis	0.07–4.01 per 1,000 children; incidence 55.0/100,000/yr (Finland)	MR null (OR 1.00); "population supplementation unlikely to reduce incidence"	RCT of 2,000 IU/day for 24 wk (n=36): no effect on disease activity or BMD	Clarke MR 2021 Tang RCT 2019 JIA review
------	---------	---------	---------	---------	-----
8	Crohn's disease	~25% of Crohn's starts in childhood; incidence 7.5/100,000/yr (Finland)	Observational only (low 25(OH)D common; malabsorption confounds)	Pediatric RCT: 2,000 vs 400 IU/day for 6 mo (n=83) raised 25(OH)D but did not change activity; adult RCT 1,200 IU/day: relapse 12% vs 29% (p=0.06)	Wingate 2014 IBD RCT MA 2018 Pediatric IBD MA
------	---------	---------	---------	---------	-----
9	Ulcerative colitis	Incidence 16.3/100,000/yr (Finland); CD exceeds UC in most other countries	Observational only	Pediatric IBD RCTs (2,000 IU/day, 6 mo) target 25(OH)D, not remission; adult IBD meta-analysis suggests fewer relapses	Pediatric IBD MA IBD RCT MA 2018
------	---------	---------	---------	---------	---
10	IgA vasculitis (HSP)	10–20 per 100,000 children/yr; most common childhood vasculitis	Observational only: 25(OH)D 15.47 vs 22.48 ng/mL in controls; lowest with nephritis	One low-quality Chinese alfacalcidol study reported fewer recurrences and less kidney damage; no RCTs	Wang IgAV 2023 HSP severity
------	---------	---------	---------	---------	---
11	Kawasaki disease	330.2 per 100,000 under-5s in Japan (2015 national survey) vs 5.4–11.4 per 100,000 under-5s in Norway, Sweden and Finland; immune-mediated vasculitis, not classic autoimmune	Observational: meta-analysis of 22 studies found lower 25(OH)D in KD; findings on coronary lesions conflict	No human trials; mouse model only	KD MA 2024 Chen 2014
------	---------	---------	---------	---------	---
12	Immune thrombocytopenia (ITP)	About 4–8 per 100,000 person-yrs in children (NCT06073925 trial record); most cases resolve	Observational only: deficiency in 80% (Lassandro, n=30); 75% below 10 ng/mL (Baghdad, n=63); severe deficiency 24% vs 6% in controls (El Mabrouk)	Sufficient 25(OH)D linked to better response in persistent/chronic ITP; only quasi-experimental trials	El Mabrouk 2023 Čulić 2016
------	---------	---------	---------	---------	---
13	Graves' disease	Rare before puberty; mainly adolescent girls	Observational only; AITD component of VITAL	Antibody-lowering effect seen in pooled AITD meta-analyses; no Graves'-specific pediatric RCT	AITD meta-analysis VitaminDWiki thyroid
------	---------	---------	---------	---------	---
14	Childhood-onset SLE	0.7 per 100,000 (Minnesota); 2.22/100,000/yr (US Medicaid)	Observational only	Positive double-blind RCT: 50,000 IU/week for 24 wk (n=40) improved SLEDAI (p=0.010), ECLAM, fatigue and bone microarchitecture	Lima 2016 RCT Lima bone RCT NCT01892748
------	---------	---------	---------	---------	---
15	Pediatric multiple sclerosis	1.12 per 100,000 person-yrs (Sweden)	Adult MR supports causal role; latitude/sun gradients	Observational pediatric: each 10 ng/mL higher 25(OH)D linked to 34% lower relapse rate (IRR 0.66); adult add-on RCTs show non-significant trends	Mowry 2010 Graves 2020 genetic Sweden POMS
------	---------	---------	---------	---------	---
16	Juvenile localized scleroderma	3.4 per million under-16s/yr (95% CI 2.7–4.1); linear subtype 2.5 (UK/Ireland surveillance, Herrick 2010)	Not reported	Not reported (only adult systemic sclerosis observational data)	VitaminDWiki systemic sclerosis
------	---------	---------	---------	---------	---
17	Juvenile dermatomyositis	1.9 per million under-16s/yr (UK)	Not reported	Not reported (used only for steroid bone protection)	—
18	Autoimmune hepatitis	0.23–0.49 per 100,000/yr (Canada, Scotland)	Not reported in children	Not reported	Scotland AIH
------	---------	---------	---------	---------	---
19	Autoimmune encephalitis (e.g., anti-NMDAR)	Rare; exact pediatric incidence not well established	Not reported	Not reported	—
------	---------	---------	---------	---------	---
20	Juvenile myasthenia gravis	10–15% of MG cases in Europe/North America vs up to 50% in Asian populations (Orphanet); 0.8–3.8 per million/yr (England, 2015–2017)	Not reported	Not reported in children	—

Cross-cutting prevention reference (adults): VITAL randomized 25,871 adults aged 50 and over to 2,000 IU/day vitamin D3 and/or omega-3 for a median of 5.3 years.[58][59] Confirmed autoimmune disease occurred in 123 people on vitamin D vs 155 on placebo (HR 0.78, 95% CI 0.61–0.99).[60][61] The effect was stronger after 2 years of use and in leaner participants (HR 0.47 at BMI 18 vs 0.90 at BMI 30).[61][62][63] No individual disease reached significance on its own,[61] and the benefit faded in the 2 years after supplementation stopped. Links: [[VITAL BMJ 2022](https://lupus.bwh.harvard.edu/wp-content/uploads/2022/01/VITAL-BMJ-Article.pdf)] [[VITAL extension](https://pubmed.ncbi.nlm.nih.gov/38272846/)] [[VitaminDWiki VITAL](https://www.vitamindwiki.com/pages/vitamin-d-reduces-autoimmune-disease-dr-campbell-video-and-transcript/)] [VitaminDWiki autoimmune overview]

Summary: Where Vitamin D Evidence Is Strongest

Prevention (strongest to weakest):

Type 1 diabetes.
- Hyppönen's 1966 northern Finland birth cohort followed 10,366 children; 81 developed diabetes. Regular infant supplementation was associated with markedly lower risk.[31]
- Meta-analyses of observational studies give a pooled OR of 0.71 for infant supplementation.[64]
- Against this: maternal intake in pregnancy is null (OR 0.95, 0.66–1.36), Mendelian randomization is null, and in Denmark's low-dose margarine-fortification natural experiment (D-Tect; 1.25 µg vitamin D per 100 g margarine, mandatory 1961–1985), Jacobsen, Hyppönen et al. (PLoS ONE 2015) found the fortification "did not change the pattern" of type 1 diabetes risk before age 15.
- Overall: suggestive, not proven.
Multiple sclerosis. Adult MR is supportive and pediatric relapse data are consistent, but there are no pediatric prevention trials.[65][66]
Psoriasis and autoimmune thyroiditis. Supported by MR (psoriasis) or observational data, and both were components of VITAL's composite outcome.[59]
Celiac disease. The U-shaped TEDDY finding argues against "more is better" in infancy.[19]
JIA and vitiligo. MR null, so supplementation is unlikely to prevent them.[13][15][40]

Treatment (best evidence first):

Childhood-onset SLE. The only positive double-blind pediatric RCT: 50,000 IU/week for 24 weeks improved disease activity and fatigue (n=40).[41][67][68]
Hashimoto's thyroiditis. Several adult RCT meta-analyses show lower TPOAb, especially in deficient patients. Antibody titres are a surrogate marker, and thyroid function generally does not change.[69][70]
New-onset type 1 diabetes. Small pediatric RCTs suggest slower C-peptide decline (preserved insulin production), but they are open-label or small and active-vitamin-D (calcitriol) trials were null.[32][71]
Psoriasis. Topical analogues are proven; oral supplementation is not.[72][73]
Alopecia areata. Intralesional or topical vitamin D has some support, but oral doses in children did not help.[36][37]
Null in pediatric RCTs: JIA and Crohn's disease. Benefit there is limited to bone health and correcting deficiency.[2][3]

Recommendations

Measure 25(OH)D in children with any of these diseases and correct deficiency (target at least 20 ng/mL, often 30 ng/mL in trials). This is justified on bone-health grounds alone, especially with steroid use, IBD or celiac disease.
Follow standard infant supplementation (400 IU/day, 10 µg). The Finnish data (2,000 IU/day in the 1960s) are hypothesis-generating, and current evidence does not justify megadoses for prevention.
Treat high-dose oral regimens as experimental outside trials. This includes the Coimbra protocol (35,000 IU/day), which is promoted on VitaminDWiki and has only uncontrolled pilot data.[74][75] These regimens require calcium monitoring.
Treat VitaminDWiki pages as useful compilations of studies, not as appraisals. Several of its headline claims (e.g., "8X less likely" for type 1 diabetes) overstate observational data that later MR and fortification studies have not confirmed.[76]

Caveats

Reverse causation and confounding:
- Most associations measure 25(OH)D after disease onset.
- Inflammation, malabsorption, obesity, glucocorticoids and reduced outdoor time all lower 25(OH)D.[1][77][78]
- One Kawasaki study even found higher 25(OH)D in children who developed coronary lesions.[79]
Dosing heterogeneity: trials used anything from 400 IU/day to 50,000 IU/week, with D2, D3, calcitriol or alfacalcidol, which makes pooling difficult.[3]
Pediatric data gaps:
- The thyroid, psoriasis, IBD relapse and VITAL data are adult.
- Rare conditions (JDM, localized scleroderma, AIH, autoimmune encephalitis, myasthenia gravis) have essentially no vitamin D data.
Ranking uncertainty: prevalence figures come from different methods (claims databases, surveys, health-record networks, registries) and countries, so ranks beyond the top 8 are approximate.
Unverified result: the vitiligo RCT result (NCT04872257) could not be independently verified.

Sources

```